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Introduction: Improving our understanding of
outbreaks due to antibiotic-resistant bacteria (ARB) and
their control is critical in the current public health
scenario. The threat of outbreaks due to ARB requires
multifaceted efforts. However, a global overview of
epidemiological characteristics of outbreaks due to
ARB and effective infection control measures is
missing. In this paper, we describe the protocol of a
systematic review aimed at mapping and characterising
the epidemiological aspects of outbreaks due to ARB
and infection control measures in European countries.
Methods and analysis: The databases MEDLINE,
Web of Knowledge and Cochrane library will be
searched using a 3-step search strategy. Selection of
articles for inclusion will be performed by 2 reviewers
using predefined eligibility criteria. All study designs
will be included if they report an outbreak and define
the microbiological methods used for microorganism
identification. The target bacteria will be methicillin-
resistant and vancomycin-resistant Staphylococcus
aureus, vancomycin-resistant Enterococcus,
ceftazidime-resistant and carbapenem-resistant
Acinetobacter baumannii, ceftazidime-resistant and
carbapenem-resistant Pseudomonas aeruginosa,
ciprofloxacin-resistant Escherichia coli, extended-
spectrum β-lactamase-producing E. coli and Klebsiella
pneumoniae, carbapenem-resistant and
carbapenamase-producing Enterobacteriaceae. Data will
be extracted using a tailored pilot tested form and the
quality of reporting will be assessed using the ORION
(Outbreak Reports and Intervention Studies Of
Nosocomial infections) tool. Data will be synthesised
and reported by the type of ARB, setting and country.
Infection control measures and bundles of measures
will be described. The effectiveness will be reported as
defined by the authors. Regression analysis will be
used to define independent factors associated with
outbreaks’ control. Heterogeneity between studies will
be assessed by forest plots and I² statistics.
Ethics and dissemination: Ethical approval is not
applicable for this study. Findings will be disseminated
through journal publication and conference
presentations and talks.
INTRODUCTION
The genetic capabilities of bacteria and indis-
criminate use of antibiotics have resulted in the
wide-spread development of resistance, hinder-
ing the effectiveness of antibiotic therapy.1–5
Notably, resistance to single antibiotic has further
progressed into multidrug resistance which
advantageously protects bacterial pathogens
against several commonly used therapeutic
agents. Multidrug resistances are rapidly evolving
in several bacterial species: most predominant
and difficult-to-deal-with multidrug-resistant
(MDR) organisms include methicillin-resistant
Staphylococcus aureus (MRSA); vancomycin-resist-
ant enterococci (VRE); extended-spectrum
β-lactamase (ESBL)-producing Escherichia coli;
and MDR-Pseudomonas aeruginosa, Acinetobacter
baumannii and Klebsiella pneumoniae.6–9
In the 2011–2012 point-prevalence survey
conducted by the European Centre for
Disease Prevention and Control (ECDC),
methicillin resistance was reported in 41% of
invasive S. aureus isolates; vancomycin
Strengths and limitations of this study
▪ Our systematic review will provide a global epi-
demiological overview of published outbreaks
due to antibiotic-resistant bacteria (ARB) and
infection control measures implemented to
control the ARB outbreak.
▪ No restriction of languages and settings (health-
care and community) will be applied.
▪ Multiple literature databases and publically
accessible national/international surveillance
systems will be searched for outbreaks due to
target ARB.
▪ Strong under-reporting of outbreaks is expected
and could limit the generalisability of results.
▪ Implemented infection control measures could
be difficult to evaluate due to heterogeneity of
national guidance documents.
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resistance in 10% of enterococci isolates; third-generation
cephalosporin resistance in 33% of all Enterobacteriaceae iso-
lates; and carbapenem resistance in 8% of
Enterobacteriaceae, 32% of P. aeruginosa and 81% of A. bau-
mannii isolates.10 Mortality from antimicrobial resistance
was estimated at 50 000 deaths per year in the USA and
Europe alone.11 Annual worldwide mortality from anti-
microbial resistance may exceed 700 000 and has been
projected to rise to 10 million by 2020, a burden larger
than that projected for neoplastic diseases.12
A well-recognised tool in the strategy to contain anti-
biotic resistance is surveillance.13–16 Based on the infor-
mation gathered, surveillance data on antimicrobial
resistance drive clinical decision-making on empiric
therapy and infection prevention policy.17 Overall, sur-
veillance enables improved patient outcome at the local
level, while guiding public health policymaking and
interventions at the national level, and helps identify
emerging threats on a global scale.18
Under the Innovative Medicines Initiative (IMI)-funded
New Drugs for Bad Bugs (ND4BB) programme, the
Combating Bacterial Resistance in Europe—Molecules
against Gram Negative Infections (COMBACTE-
MAGNET) consortium is currently working on an unpre-
cedented collaboration called EPI-Net (the Epidemiology
Network) among representative stakeholders, experts
and industry from major European countries. EPI-Net’s
objective is to address the limitations of current
healthcare-associated and antibiotic-resistant infections
surveillance within Europe.19 20 As part of this effort and
in collaboration with the DRIVE-AB consortium (IMI
COMBACTE Project) a systematic review of the literature
on outbreak reports, named EMBARGO (EpideMiology
and control measures of outBreaks due to
Antibiotic-Resistant orGanisms in EurOpe), is planned.
The objective of the study will be to:
▸ Systematically review articles reporting outbreaks due
to antibiotic-resistant bacteria (ARB) in Europe to
map and describe the epidemiological characteristics
of the outbreaks and infection control measures.
▸ Analyse effectiveness of infection control measures or
bundles of measures to control the outbreaks.
▸ Assess quality of outbreak studies.
We report here the protocol.
METHODS AND ANALYSIS
Study design
A systematic review of the literature and a meta-analysis
(when possible) in accordance with PRISMA statement21
will be performed in order to identify most effective
infection control measures or bundles of measures to
reduce or prevent the spread of ARB.
Inclusion criteria
The study must report an outbreak of target ARB and
standard laboratory techniques for detection of microor-
ganisms. An outbreak will be defined as an unusual or
unexpected increase of cases of infection due to target
ARB with or without molecular analysis of the strain.22
The target ARB will be: MRSA, vancomycin-resistant S.
aureus, VRE, ceftazidime-resistant and carbapenem-
resistant A. baumannii, ceftazidime-resistant and
carbapenem-resistant P. aeruginosa, ciprofloxacin-resistant
E. coli, ESBL-producing E. coli and K. pneumoniae,
carbapenem-resistant and carbapenamase-producing
Enterobacteriaceae. Since the definition of an ESBL produ-
cer has changed over time,23 24 the following definitions
for ESBL will be included: (1) resistant to ceftazidime
and/or ceftriaxone (the two may have different detection
at different locations and may have changed over time),
(2) phenotypic confirmation (eg, using β-lactamase
inhibitor combination), and (3) gene identification
(likely to exist initially only in single isolates, and recently
for larger number of strains). Carbapenem resistance will
be reported according to authors’ definitions. European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) or Clinical and Laboratory Standards Institute
(CLSI) clinical breakpoints will be reported, when avail-
able. All settings (community and healthcare facilities)
and all population groups (elderly, children, immuno-
compromised, etc), regardless of age, racial and ethnic
backgrounds will be considered.
Search strategy
We will identify all published literature reporting out-
breaks due to target ARB and include all European
studies reporting outbreaks. Publications will be
searched through a systematic search of MEDLINE, Web
of Knowledge and Cochrane library using the following
terms: name of target ARB combined with ‘outbreak OR
outbreaks OR pandemic OR pandemics OR epidemic
OR epidemics OR infectious disease outbreak OR infec-
tious disease outbreaks OR disease outbreak OR disease
outbreaks OR emergence’. Searches will be limited to
31.05.2016 (‘0001/01/01’[PDat]: ‘2016/05/31’[PDat];
see online supplementary material 1).
A three-step search strategy will be used: (1) text
words contained in the title, abstract and the index
(MeSH) terms in MEDLINE; (2) keywords and index
terms across all other included databases; and (3) refer-
ence list of all retrieved articles for other potentially rele-
vant studies. No language restriction will be applied. In
countries with mandatory reporting of outbreaks due to
the target ARB, publicly available databases will also be
included. Experts in surveillance will be contacted for
unpublished data on local outbreaks.
Selection process
A two-step selection process will be performed by two
independent reviewers. Titles and abstracts of the
retrieved articles will be initially screened and non-
relevant studies will be excluded. The reasons for exclu-
sion will be noted. For potentially eligible studies, the
full text will then be obtained and assessed for relevance
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and duplication against the predefined selection
criteria.
Data extraction process and management
All published articles obtained based on the literature
search will be downloaded into a reference management
database and used to document further screening. Data
extraction from the included articles will be carried out
and managed using Epi Info V.7.0 (CDC). Two inde-
pendent reviewers will extract data using a standardised
data extraction form which will be first pilot tested on a
representative sample of articles. We will cross verify data
and any discrepancies and inconsistencies will be dis-
cussed and sorted out by consensus.
The following data will be extracted: article-related vari-
ables: author, contact details of the corresponding
author, institute, country, year of publication, year of out-
break, title of the article, journal; study-associated vari-
ables: data collection period, study design, sampling,
study setting (hospital based, other healthcare facilities,
community based), population profile; sociodemo-
graphic characteristics: age, sex; ARB-specific character-
istics: identification method, colonisation/infection;
outbreak-specific characteristics: type of screening
(serum, throat swab, rectal swab, etc), type of infection,
how the outbreak was detected (routine surveillance,
reported by general practitioners, etc), number of
patients screened; number of patients tested positive;
number of patients infected and colonised; date of senti-
nel case; date of intervention, number of cases before the
intervention, date of last case, endemicity, duration of
outbreak, country and city/region of the outbreak, any
mode of spread reported, clonality (clonal vs polyclonal/
plasmid/gene spread if known); infection control mea-
sures: type of infection control measures, audit, duration
of implementation, bundles, feedback. The infection
control measures will include education (any educational
measure implemented to control the ARB outbreak) and
antimicrobial stewardship programmes (any programme
aimed at improving prescription of antimicrobials imple-
mented to control the ARB outbreak).
Quality assessment—risk of bias in individual studies
Quality appraisal will be performed using the ORION
(Outbreak Reports and Intervention Studies of
Nosocomial Infections) statement which guides reporting
of observational studies and outbreak reporting.25 Two
reviewers will independently assess the quality of each
included study and any disagreements that arise will be
resolved through discussion, or with a third reviewer.
Data synthesis and analysis
We will synthesise data by ARB type, setting and country.
Attack rates will be defined as the percentage of observed
patients who were either colonised or infected by the
target ARB in the overall population, while infection
rates as the percentage of patients who were infected
among those colonised. Attack rates and infection rates
will be estimated by ARB and setting. Effectiveness of
measures in controlling the outbreaks, as reported by the
authors, will be analysed by single measures and by associ-
ation of measures (when possible). Regression analysis
will be used to define variables of success/failure of infec-
tion control measures used to control the outbreaks.
Heterogeneity will be assessed through visual inspection
of the forest plots to detect overlapping CIs and also by
applying the I² statistics. A priori determined sources of
heterogeneity will be studied using meta-regression.
Epidemiological factors influencing the outbreaks to be
self-limiting or persistent will be analysed using
meta-regression. Results will be stratified by target ARB,
country and time period. STATA statistical software
(StataCorp 2015, Release 14, College Station, Texas,
USA) will be used to conduct these analyses. As the sys-
tematic review aims to study the outbreaks, studying pub-
lication bias using funnel plots is not applicable. We will
assess publication bias in a subset of data by external val-
idation with surveillance data on outbreaks where out-
break reporting is mandatory and publicly available.
DISCUSSION
This systematic review, carried out contextually to the estab-
lishment of the COMBACTE-MAGNET, EPI-Net will identify
and summarise the relevant evidence on the epidemio-
logical aspects of outbreaks due to ARB and effectiveness of
infection control measures in reducing and/or controlling
the spread of ARB in healthcare and community settings.
Strengths (ie, inclusion of unpublished data, huge
sample size and regression analysis) and limitations
(high heterogeneity of settings, country public health
indications, mandatory reporting, laboratory facilities,
different ARB transmission modalities and publication
bias) of the review will be discussed and gaps in the evi-
dence will also be highlighted. The findings of this
review and those of other similar reviews will be com-
pared (if identified) for the degree of consistency.
The evaluation of the quality of the studies will help in
defining grey areas of the literature and outbreaks data
reporting. Analysis of effectiveness of infection control
measures could help future guidance documents in
streamlining indications on outbreak control according
to the type of ARB and setting and suggest areas for
future studies.
ETHICS AND DISSEMINATION
Since only published data will be used for the study, no
formal ethical approval is required. The systematic
review will be submitted for publication. The results of
the review and data will be presented in conferences
and general meetings with internal and external stake-
holders, and will also be discussed with policymakers for
the common purpose of developing a framework of
what constitutes responsible use of existing and new
antibiotics.
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